Wikipedia

Nalidixic acid

Nalidixic acid (tradenames Nevigramon, NegGram, Wintomylon and WIN 18,320) is the first of the synthetic quinolone antibiotics.

Nalidixic acid
Clinical data
Trade namesNegGram, Wintomylon, others
AHFS/Drugs.comConsumer Drug Information
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • US: Not FDA approved
Pharmacokinetic data
Protein binding90%
MetabolismPartially Hepatic
Elimination half-life6-7 hours, significantly longer in renal impairment
Identifiers
  • 1-Ethyl-7-methyl-4-oxo-[1,8]naphthyridine-3-carboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.006.241 Edit this at Wikidata
Chemical and physical data
FormulaC12H12N2O3
Molar mass232.239 g·mol−1
3D model (JSmol)
  • O=C\2c1c(nc(cc1)C)N(/C=C/2C(=O)O)CC
  • InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17) checkY
  • Key:MHWLWQUZZRMNGJ-UHFFFAOYSA-N checkY
  (verify)

In a technical sense, it is a naphthyridone, not a quinolone: its ring structure is a 1,8-naphthyridine nucleus that contains two nitrogen atoms, unlike quinoline, which has a single nitrogen atom.[1]

Synthetic quinolone antibiotics were discovered by George Lesher and coworkers as a byproduct of chloroquine manufacture in the 1960s;[2] nalidixic acid itself was used clinically, starting in 1967.

Nalidixic acid is effective primarily against Gram-negative bacteria, with minor anti-Gram-positive activity. In lower concentrations, it acts in a bacteriostatic manner; that is, it inhibits growth and reproduction. In higher concentrations, it is bactericidal, meaning that it kills bacteria instead of merely inhibiting their growth.

It has historically been used for treating urinary tract infections, caused, for example, by Escherichia coli, Proteus, Shigella, Enterobacter, and Klebsiella. It is no longer clinically used for this indication in the US as less toxic and more effective agents are available. The marketing authorization for nalidixic acid has been suspended throughout the EU.[3]

It is also a tool in studies as a regulation of bacterial division. It selectively and reversibly blocks DNA replication in susceptible bacteria. Nalidixic acid and related antibiotics inhibit a subunit of DNA gyrase and topoisomerase IV and induce formation of cleavage complexes.[4] It also inhibits the nicking-closing activity on the subunit of DNA gyrase that releases the positive binding stress on the supercoiled DNA.

Adverse effects

edit

Hives, rash, intense itching, or fainting soon after a dose may be a sign of anaphylaxis. Common adverse effects include rash, itchy skin, blurred or double vision, halos around lights, changes in color vision, nausea, vomiting, and diarrhea. Nalidixic acid may also cause convulsions and hyperglycemia,[5] photosensitivity reactions,[6] and sometimes hemolytic anemia,[7][8] thrombocytopenia[9] or leukopenia. Particularly in infants and young children, has been reported occasionally increased intracranial pressure.[10][11][12]

Overdose

edit

In case of overdose the patient experiences headache, visual disturbances, balance disorders, mental confusion, metabolic acidosis and seizures.[13]

Spectrum of bacterial susceptibility and resistance

edit

Aeromonas hydrophila, Clostridium and Haemophilus are generally susceptible to nalidixic acid, while other bacteria such as Bifidobacteria, Lactobacillus, Pseudomonas and Staphylococcus are resistant.[14] Salmonella enterica serovar Typhimurium strain ATCC14028 acquires nalidixic acid resistance when gyrB gene is mutated (strain IR715).[15]

See also

edit

References

edit
  1. ^ Emmerson AM, Jones AM (May 2003). "The quinolones: decades of development and use". The Journal of Antimicrobial Chemotherapy. 51 (Suppl 1): 13–20. doi:10.1093/jac/dkg208. PMID 12702699.
  2. ^ Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage RP (September 1962). "1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents". Journal of Medicinal and Pharmaceutical Chemistry. 5 (5): 1063–1065. doi:10.1021/jm01240a021. PMID 14056431.
  3. ^ "Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics". European Medicines Agency. 11 March 2019.
  4. ^ Pommier Y, Leo E, Zhang H, Marchand C (May 2010). "DNA topoisomerases and their poisoning by anticancer and antibacterial drugs". Chemistry & Biology. 17 (5): 421–433. doi:10.1016/j.chembiol.2010.04.012. PMC 7316379. PMID 20534341.
  5. ^ Fraser AG, Harrower AD (December 1977). "Convulsions and hyperglycaemia associated with nalidixic acid". British Medical Journal. 2 (6101): 1518. doi:10.1136/bmj.2.6101.1518. PMC 1632822. PMID 589309.
  6. ^ Ramsay CA (August 1973). "Photosensitivity from nalidixic acid". Proceedings of the Royal Society of Medicine. 66 (8): 747. doi:10.1177/003591577306600805. PMC 1645105. PMID 4733958.
  7. ^ Gilbertson C, Jones DR (November 1972). "Haemolytic anaemia with nalidixic acid". British Medical Journal. 4 (5838): 493. doi:10.1136/bmj.4.5838.493-a. PMC 1786728. PMID 4653901.
  8. ^ Tafani O, Mazzoli M, Landini G, Alterini B (October 1982). "Fatal acute immune haemolytic anaemia caused by nalidixic acid". British Medical Journal. 285 (6346): 936–937. doi:10.1136/bmj.285.6346.936-a. PMC 1499997. PMID 6811074.
  9. ^ Meyboom RH (October 1984). "Thrombocytopenia induced by nalidixic acid". British Medical Journal. 289 (6450): 962. doi:10.1136/bmj.289.6450.962. PMC 1443179. PMID 6435742.
  10. ^ Boréus LO, Sundström B (June 1967). "Intracranial hypertension in a child during treatment with nalidixic acid". British Medical Journal. 2 (5554): 744–745. doi:10.1136/bmj.2.5554.744. PMC 1841777. PMID 6025983.
  11. ^ Kremer L, Walton M, Wardle EN (November 1967). "Nalidixic acid and intracranial hypertension". British Medical Journal. 4 (5577): 488. doi:10.1136/bmj.4.5577.488-a. PMC 1748506. PMID 6055749.
  12. ^ Deonna T, Guignard JP (September 1974). "Acute intracranial hypertension after nalidixic acid administration". Archives of Disease in Childhood. 49 (9): 743. doi:10.1136/adc.49.9.743. PMC 1649016. PMID 4419059.
  13. ^ Eizadi-Mood N (March 2006). "Nalidixic acid overdose and metabolic acidosis". CJEM. 8 (2): 78. doi:10.1017/s148180350001349x. PMID 17175866.
  14. ^ "Nalidixic acid spectrum of bacterial susceptibility and Resistance" (PDF). Toku-E. 2011-09-14. Archived from the original (PDF) on 2016-01-10. Retrieved 2012-05-14.
  15. ^ Stojiljkovic I, Bäumler AJ, Heffron F (March 1995). "Ethanolamine utilization in Salmonella typhimurium: nucleotide sequence, protein expression, and mutational analysis of the cchA cchB eutE eutJ eutG eutH gene cluster". Journal of Bacteriology. 177 (5): 1357–66. doi:10.1128/jb.177.5.1357-1366.1995. PMC 176743. PMID 7868611.
edit
Retrieved from "https://en.wiki.x.io/w/index.php?title=Nalidixic_acid&oldid=1262009584"